126 related articles for article (PubMed ID: 30182430)
1. Comparative pharmacokinetics of danofloxacin in healthy and Pasteurella multocida infected ducks.
Xiao X; Lan W; Wang Y; Jiang L; Jiang Y; Wang Z
J Vet Pharmacol Ther; 2018 Dec; 41(6):912-918. PubMed ID: 30182430
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics of florfenicol in healthy and Pasteurella multocida-infected Gaoyou ducks.
Lan W; Xiao X; Jiang Y; Jiang L; Zhao X; Yu Z; Zhu B; Li C; Bian L; Wang Z
J Vet Pharmacol Ther; 2019 May; 42(3):355-360. PubMed ID: 30912167
[TBL] [Abstract][Full Text] [Related]
3. Plasma and tissue pharmacokinetics of danofloxacin in healthy and in experimentally infected chickens with Pasteurella multocida.
Zeng Z; Deng G; Shen X; Rizwan-Ul-Haq M; Zeng D; Ding H
J Vet Pharmacol Ther; 2011 Feb; 34(1):101-4. PubMed ID: 21219355
[No Abstract] [Full Text] [Related]
4. Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks.
Tohamy MA
Br Poult Sci; 2011 Oct; 52(5):639-44. PubMed ID: 22029792
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.
Qu Y; Qiu Z; Cao C; Lu Y; Sun M; Liang C; Zeng Z
BMC Vet Res; 2015 Dec; 11():294. PubMed ID: 26631082
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cefquinome in healthy and Pasteurella multocida-infected rabbits.
Elazab ST; Schrunk DE; Griffith RW; Ensley SM; Dell'Anna G; Mullin K; Elsayed MG; Amer MS; El-Nabtity SM; Hsu WH
J Vet Pharmacol Ther; 2018 Jun; 41(3):374-377. PubMed ID: 29383736
[TBL] [Abstract][Full Text] [Related]
7. Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves.
Balaje RM; Sidhu PK; Kaur G; Rampal S
Res Vet Sci; 2013 Dec; 95(3):1114-24. PubMed ID: 23941961
[TBL] [Abstract][Full Text] [Related]
8. Impact of bovine respiratory disease on the pharmacokinetics of danofloxacin and tulathromycin in different ages of calves.
Mzyk DA; Bublitz CM; Martinez MN; Davis JL; Baynes RE; Smith GW
PLoS One; 2019; 14(6):e0218864. PubMed ID: 31233558
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue-cage model in yellow cattle.
Shan Q; Wang J; Yang F; Ding H; Liang C; Lv Z; Li Z; Zeng Z
J Vet Pharmacol Ther; 2014 Jun; 37(3):222-30. PubMed ID: 24033339
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.
Lees P; Potter T; Pelligand L; Toutain PL
J Vet Pharmacol Ther; 2018 Feb; 41(1):28-38. PubMed ID: 28736817
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of avian Escherichia coli and Pasteurella multocida to danofloxacin and five other antimicrobials.
Raemdonck DL; Tanner AC; Tolling ST; Michener SL
Avian Dis; 1992; 36(4):964-7. PubMed ID: 1336664
[TBL] [Abstract][Full Text] [Related]
12. Influence of Pasteurella multocida infection on the pharmacokinetic behavior of marbofloxacin after intravenous and intramuscular administrations in rabbits.
Abo-el-Sooud K; Goudah A
J Vet Pharmacol Ther; 2010 Feb; 33(1):63-8. PubMed ID: 20444027
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic integration of cefquinome against Pasteurella Multocida in a piglet tissue cage model.
Zhang L; Wu X; Huang Z; Kang Z; Chen Y; Shen X; Cai Q; Ding H
J Vet Pharmacol Ther; 2019 Jan; 42(1):60-66. PubMed ID: 30407642
[TBL] [Abstract][Full Text] [Related]
14. Integrated pharmacokinetic-Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets.
Zeng QL; Mei X; Su J; Li XH; Xiong WG; Lu Y; Zeng ZL
BMC Vet Res; 2017 Jun; 13(1):178. PubMed ID: 28619095
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic relationship of marbofloxacin for Escherichia coli and Pasturella multocida following repeated intramuscular administration in goats.
Bhardwaj P; Sidhu PK; Saini SPS; M B D; Rampal S
J Vet Pharmacol Ther; 2019 Jul; 42(4):430-439. PubMed ID: 31102281
[TBL] [Abstract][Full Text] [Related]
16. New interpretive criteria for danofloxacin antibacterial susceptibility testing against Mannheimia haemolytica and Pasteurella multocida associated with bovine respiratory disease.
Sweeney MT; Papich MG; Watts JL
J Vet Diagn Invest; 2017 Mar; 29(2):224-227. PubMed ID: 28064562
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration.
Aliabadi FS; Lees P
Am J Vet Res; 2001 Dec; 62(12):1979-89. PubMed ID: 11763192
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits.
Hanan MS; Riad EM; el-Khouly NA
Dtsch Tierarztl Wochenschr; 2000 Apr; 107(4):151-5. PubMed ID: 10829566
[TBL] [Abstract][Full Text] [Related]
19. Pasteurella multocida in scavenging family chickens and ducks: carrier status, age susceptibility and transmission between species.
Mbuthia PG; Njagi LW; Nyaga PN; Bebora LC; Minga U; Kamundia J; Olsen JE
Avian Pathol; 2008 Feb; 37(1):51-7. PubMed ID: 18202950
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.
Lees P; Pelligand L; Illambas J; Potter T; Lacroix M; Rycroft A; Toutain PL
J Vet Pharmacol Ther; 2015 Oct; 38(5):457-70. PubMed ID: 25669418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
